Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Amol, Tendolkar"'
Autor:
Hongyun Zhao, Amol Tendolkar, Yuxiang Ma, Sai Praneeth Reddy Bathena, Jennifer Sheng, Wenfeng Fang, Li Zhang
Publikováno v:
Oncologist
Lessons Learned The overall safety profiles of ipilimumab 3 mg/kg and 10 mg/kg administered every 3 weeks, were consistent between Chinese patients with solid tumors in the current study and patients from previous U.S. ipilimumab monotherapy studies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::144f8ceb2022f957935b6cdc38ef5d4a
https://pubmed.ncbi.nlm.nih.gov/33105036
https://pubmed.ncbi.nlm.nih.gov/33105036
Autor:
Manish Gupta, Amit Roy, Amol Tendolkar, Michael Robbins, Johanna R Mora, Chaitali Passey, Robert Dodge, Akintunde Bello, Jennifer Sheng
Publikováno v:
Clinical pharmacokinetics. 57(3)
Novel treatment options are needed to improve long-term outcomes for patients with multiple myeloma (MM). In this article, we comprehensively review the clinical pharmacology of elotuzumab, a first-in-class monoclonal anti-SLAMF7 antibody approved in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e98f42754fb7e77fb26a65e1daa95696
https://pubmed.ncbi.nlm.nih.gov/28779463
https://pubmed.ncbi.nlm.nih.gov/28779463
Autor:
Yuxiang Ma, Yang Zhang, Hongyun Zhao, Li Zhang, Dong Xu, Amol Tendolkar, Wenfeng Fang, Shaodong Hong, Jennifer Sheng, Yuanyuan Zhao, Lu Chen, Yunpeng Yang
Publikováno v:
The Oncologist
Lessons LearnedNivolumab treatment at doses of 3 mg/kg once every 2 weeks (Q2W), 240 mg Q2W, and 360 mg once every 3 weeks was well tolerated in the Chinese population, with no new safety signals identified. Comparison of intensive pharmacokinetic pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8817de460040a98ef5e9995779e039c5
https://doi.org/10.1634/theoncologist.2019-0284
https://doi.org/10.1634/theoncologist.2019-0284
Autor:
Sarah Pett, Karen MacRae, Julie M. Strizki, Richard Norris, Sean Emery, Amol Tendolkar, Kenneth M. Williams, Michael McCarthy, David A. Cooper
Publikováno v:
Antiviral Therapy. 14:111-115
Background SCH532706 is a novel small molecule chemokine receptor-5 (CCR5) antagonist with high in vitro potency (mean 90% inhibitory concentration [IC90] 0.15– 7.0 nM) against diverse HIV type-1 (HIV-1) isolates. Methods A single arm study was und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1d43f2484d4668fc31cc0a0b44b9416
https://doi.org/10.1177/135965350901400112
https://doi.org/10.1177/135965350901400112
Autor:
Ashraf Badros, Jesus G. Berdeja, Amol Tendolkar, Manish Gupta, Eric Bleickardt, Prashni Paliwal, Jonathan L. Kaufman, Ravi Vij, Sundar Jagannath, Jeffrey A. Zonder, Mark Lynch, Robert F. Manges
Publikováno v:
Clinical lymphoma, myeloma & leukemia
Renal impairment is associated with a poor prognosis in patients with multiple myeloma (MM), and more treatment options are needed. The pharmacokinetics of elotuzumab, a humanized IgG1 monoclonal antibody, combined with lenalidomide and dexamethasone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5072cdafc0f56f1f7ebea06a82e254c4
https://pubmed.ncbi.nlm.nih.gov/26795075
https://pubmed.ncbi.nlm.nih.gov/26795075
Autor:
Amol Tendolkar, Jun-Sheng Wang, Hong Xiao, Richard Malamut, Oleksandr Sverdlov, Sanjay Keswani, Ishani Savant
Publikováno v:
Alzheimer's & Dementia. 9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a94bfa16c04a2b09911a46d729672b50
https://doi.org/10.1016/j.jalz.2013.05.1378
https://doi.org/10.1016/j.jalz.2013.05.1378
Autor:
Robert D. Shamburek, Amol Tendolkar, Edrick L Candler, William H. Barr, Elizabeth M Zola, Milo D Hilty, Bertram Parker, Shie-Ming Hwang
Publikováno v:
Clinical Pharmacology & Therapeutics. 56:279-285
Differences in extent of amoxicillin absorption from various regions of the gastrointestinal tract were determined and compared with the same dose administered orally. Nine healthy men were intubated at a proximal (duodenum or jejunum) or distal (ile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::527df4c47ad15bbc7575d03eb620cbae
https://doi.org/10.1038/clpt.1994.138
https://doi.org/10.1038/clpt.1994.138
Publikováno v:
Journal of clinical pharmacology. 52(11)
The aim of this study was to evaluate the effect of food on the oral bioavailability of preladenant, a novel adenosine A(2A) receptor antagonist. This open-label, randomized, single-dose, 2-way crossover study evaluated the effects of a high-fat, hig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::018d820b2ca5b6acd5cc414d7c0111cf
https://pubmed.ncbi.nlm.nih.gov/22167566
https://pubmed.ncbi.nlm.nih.gov/22167566
Autor:
Sarah L, Pett, Michael C, McCarthy, David A, Cooper, Karen, MacRae, Amol, Tendolkar, Richard, Norris, Julie M, Strizki, Kenneth M, Williams, Sean, Emery
Publikováno v:
Antiviral therapy. 14(1)
SCH532706 is a novel small molecule chemokine receptor-5 (CCRS) antagonist with high in vitro potency (mean 90% inhibitory concentration [IC90] 0.15-7.0 nM) against diverse HIV type-1 (HIV-1) isolates.A single arm study was undertaken to examine the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::87d55b02c50354940f9862e7bf9f1cdf
https://pubmed.ncbi.nlm.nih.gov/19320244
https://pubmed.ncbi.nlm.nih.gov/19320244
Autor:
Peter H. Hinderling, Michael Seiberling, Cathryn M. Dee, Amol Tendolkar, William H. Barr, Helga Duerr
Publikováno v:
Journal of clinical pharmacology. 35(7)
Using a 3 x 3 Latin Square design, a possible interaction between diprafenone HCl a class IC antiarrhythmic drug with nonspecific beta-antagonist activity and propranolol HCl was investigated in nine young, healthy, caucasian, male volunteers. The vo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1606128de8f181f0ecf6bab8f5da3c0e
https://pubmed.ncbi.nlm.nih.gov/7560253
https://pubmed.ncbi.nlm.nih.gov/7560253